Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
The animal diagnostic testing company is having one-time issues with taxes, currency changes, and macroeconomic issues
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-28 20:10:11.758473.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Catalyst One analyzer. Source: Idexx Laboratories.
Idexx Laboratories (IDXX +0.01%) reported solid third-quarter earnings on Wednesday. The look forward, though, wasn't nearly as pleasant for the animal diagnostic testing company.
Idexx Laboratories results: The raw numbers
| Metric |
Q3 2015 Actuals |
Q3 2014 Actuals |
Growth (YOY) |
|---|---|---|---|
|
Revenue |
$406 million |
$384 million |
6% |
|
Income from operations |
$71.9 million |
$72.2 million |
(0.4%) |
|
Earnings per share |
$0.48 |
$0.52 |
(7.7%) |
What happened with Idexx Laboratories this quarter?
What management had to say
Jonathan Ayers, Idexx's chairman and CEO, explained why the revenue guidance was reduced, "This outlook reflects moderated market growth trends in Europe and recent macroeconomic impacts, including effects from foreign currency erosion, limiting emerging-market gains." For the adjusted earnings-per-share revision, Ayers blamed "additional headwinds from recent foreign currency changes in emerging markets and a higher effective tax rate, affected by updated estimates for regional profit mix including foreign currency impacts." Taxes, currency changes, and macroeconomic issues -- things out of Idexx's control -- are a pretty good excuse for lowered guidance.
In addition to tests that are run by veterinarians, Idexx runs a reference laboratory where samples can be sent for testing, which is growing quite nicely and taking market share. "I believe the 13% organic growth in the third quarter is indicative of the cumulative success that we're having in the reference lab modality," Ayers said. "I think that's higher than the market growth. And if your growth is higher than the market growth for lab modality, then by definition you're gaining share." .
That's of course true only if the growth is coming from volume, not price increases, which CFO Brian McKeon confirmed was the case. Management didn't say which company was losing market share, but VCA (WOOF +0.00%) isn't growing nearly as fast. VCA reported that laboratory revenue increased 9.1% in the third quarter, but some of that was because of an acquisition. On a same-store basis, VCA's laboratory revenue increased only 6%.
Looking forward
Despite the strong third quarter, the outlook for the rest of this year and 2016 isn't nearly as strong. Management guided for next year's normalized organic revenue growth in the 8% to 9% range. And the bottom line will look even worse, with the stronger dollar and higher taxes expected to have a drag on earnings. Management guided for adjusted earnings per share to grow only 1% to 5% next year.
While it's hard to get excited about the tepid growth, the items reducing the growth are mostly one-time troubles that are out of the company's hands. If Idexx continues to perform well, placing instruments and taking market share from competitors, 2017 growth will look a lot better.